List of Triesence drug patents
Triesence is owned by Novartis.
Triesence contains Triamcinolone Acetonide.
Triesence has a total of 2 drug patents out of which 0 drug patents have expired.
Triesence was authorised for market use on 29 November, 2007.
Triesence is available in injectable;intravitreal dosage forms.
Triesence can be used as visualization during vitrectomy procedures; treatment of ophthalmic disorders.
The generics of Triesence are possible to be released after 17 December, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8211880 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(5 years from now) | |
| US8128960 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(6 years from now) | |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 November, 2007
Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders
Dosage: INJECTABLE;INTRAVITREAL
TRIESENCE family patents
5
United States
1
South Africa
1
Denmark
1
Mexico
1
Australia
1
Hong Kong
1
Slovenia
1
Russia
1
Uruguay
1
Argentina
1
Brazil
1
Portugal
1
Spain
1
Korea, Republic of
1
Poland
1
Chile
1
Taiwan, Province of China
1
China
1
Japan
1
Canada
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic